Use of cannabidiol for off-label treatment of patients with refractory focal, genetic generalised and other epilepsies
Abstract Background In randomized controlled trials, add-on cannabidiol (CBD) has been shown to reduce seizure frequency in patients with Lennox-Gastaut syndrome, Dravet syndrome and Tuberous sclerosis complex. Real-world studies provide insights into the drug’s profile in other off-label indication...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-07-01
|
| Series: | Neurological Research and Practice |
| Online Access: | https://doi.org/10.1186/s42466-025-00408-w |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Be the first to leave a comment!